Patents by Inventor Richard J. Perner

Richard J. Perner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRPA1 ANTAGONISTS
    Publication number: 20090264480
    Abstract: Compounds of formula (I) wherein R1, R2, R3, and Y are defined in the description are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: January 2, 2009
    Publication date: October 22, 2009
    Applicant: Abbott Laboratories
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • TRPA1 Antagonists
    Publication number: 20090176883
    Abstract: Compounds of formula (I) wherein R1, R2, R3, m, and Y are defined in the specification are TRPA1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: January 2, 2009
    Publication date: July 9, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Richard J. Perner, Michael E. Kort, Stanley DiDomenico, Jun Chen, Anil Vasudevan
  • TRPV1 ANTAGONISTS
    Publication number: 20090124666
    Abstract: Compounds of formula (I) wherein R1, R2, R4, and W are defined in the description are TRPV 1 antagonists with CNS penetration. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Application
    Filed: October 23, 2008
    Publication date: May 14, 2009
    Applicant: ABBOTT LABORATORIES
    Inventors: Richard J. Perner, John R. Koenig, Stanley Didomenico, JR., Erol K. Bayburt, Jerome F. Daanen, Arthur Gomtsyan, Michael E. Kort, Philip R. Kym, Robert G. Schmidt, Anil Vasudevan, Eric Voight
  • Antagonists of the vanilloid receptor subtype 1 (VR1) and use thereof
    Patent number: 7504520
    Abstract: The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: March 17, 2009
    Assignee: Abbott Laboratories
    Inventors: Arthur Gomtsyan, Richard J. Perner, John R. Koenig, Margaret Chi-Ping Hsu, Dilinie P. Fernando, Chih-Hung Lee
  • FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR
    Publication number: 20080214524
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 4, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: CHIH-HUNG LEE, EROL K. BAYBURT, STANLEY DIDOMENICO, IRENE DRIZIN, ARTHUR R. GOMTSYAN, JOHN R. KOENIG, RICHARD J. PERNER, ROBERT G. SCHMIDT, SEAN C. TURNER, TAMMIE K. WHITE, GUO ZHU ZHENG
  • NOVEL AMIDES USEFUL FOR TREATING PAIN
    Publication number: 20080153809
    Abstract: The present invention relates to compounds of formula (I-VII) or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R6, R7 and R8 are defined herein. The present invention also relates to methods of treating pain using these compounds and pharmaceutical compositions including these compounds.
    Type: Application
    Filed: February 19, 2008
    Publication date: June 26, 2008
    Applicant: ABBOTT LABORATORIES
    Inventors: CHIH-HUNG LEE, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
    Patent number: 7335678
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2, and L are defined in the description.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: February 26, 2008
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 7074805
    Abstract: The isoquinoline compounds of formula (I) are VR1 antagonists that are useful in treating pain, inflammation, thermal hyperalgesia, urinary incontinence and bladder over activity. The “R”, “Z” and “L” variables are defined in the disclosure and the “X” variables are defined as follows: X1 is CR1; X2 is selected from the group consisting of N and CR2; X3 is selected from the group consisting of N and CR3; X4 is CR4; and X5 is selected from the group consisting of N and C.
    Type: Grant
    Filed: February 11, 2003
    Date of Patent: July 11, 2006
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Patent number: 6933311
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: August 23, 2005
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Jr., Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Jr., Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Trisubstituted-N-[(1S)-1,2,3,4-Tetrahydro-1-naphthalenyl]benzamides which inhibit P2X3 and P2X2/3 containing receptors
    Patent number: 6831193
    Abstract: Compounds of formula (I) are novel P2X3 and P2X2/P2X3 antagonists which are useful in treating pain, urinary incontinence and bladder overactivity.
    Type: Grant
    Filed: May 10, 2002
    Date of Patent: December 14, 2004
    Assignee: Abbott Laboratories
    Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
  • Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor
    Publication number: 20040209884
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: May 10, 2004
    Publication date: October 21, 2004
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Publication number: 20040157849
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: August 5, 2003
    Publication date: August 12, 2004
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Publication number: 20030158198
    Abstract: Compound of formula (I) 1
    Type: Application
    Filed: February 11, 2003
    Publication date: August 21, 2003
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
    Publication number: 20030158188
    Abstract: Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.
    Type: Application
    Filed: February 20, 2002
    Publication date: August 21, 2003
    Inventors: Chih-Hung Lee, Erol K. Bayburt, Stanley DiDomenico, Irene Drizin, Arthur R. Gomtsyan, John R. Koenig, Richard J. Perner, Robert G. Schmidt, Sean C. Turner, Tammie K. White, Guo Zhu Zheng
  • Trisubstituted-N-[(1S)-1,2,3,4-terrahydro-1-naphthalenyl]benzamides which inhibit P2X2/3 containing receptors
    Publication number: 20030083359
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: May 10, 2002
    Publication date: May 1, 2003
    Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
  • Trisubstituted-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit P2X3 and P2X2/3 containing receptors
    Publication number: 20020173665
    Abstract: Compounds of formula (I) 1
    Type: Application
    Filed: May 18, 2001
    Publication date: November 21, 2002
    Inventors: Chih-Hung Lee, Richard J. Perner, Daniel P. Larson, John R. Koenig, Arthur R. Gomtsyan, Guo Zhu Zheng, Stanley DiDomenico, Andrew O. Stewart, Erol K. Bayburt
  • 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
    Patent number: 6030969
    Abstract: A compound having the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are defined, a method for inhibiting adenosine kinase by administering a compound thereof, a pharmaceutical composition comprising a therapeutically effective amount of a compound thereof above in combination with a pharmaceutically acceptable carrier, a method of treating cerebral ischemia, epilepsy, pain, nociperception, inflammation and sepsis in a mammal in need of such treatment, comprising administering to the mammal a therapeutically effective amount of a compound thereof, and methods for preparation thereof.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: February 29, 2000
    Assignee: Abbott Laboratories
    Inventors: Shripad S. Bhagwat, Richard J. Perner, Yu-Gui Gu
  • Dopamine agonists
    Patent number: 5621133
    Abstract: Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: April 15, 1997
    Inventors: Michael P. DeNinno, Richard J. Perner
  • Dopamine agonists
    Patent number: 5591884
    Abstract: Novel compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters and amides thereof, whereinA is --O--, --S-- or --CR.sup.2 R.sup.8 --;R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10, X and Y are specifically defined; andup to one combination of (a) R.sup.2 and R.sup.5, (b) R.sup.5 and R.sup.6, (c) R.sup.5 and R.sup.7, (d) R.sup.6 and R.sup.7, and (e) R.sup.7 and Y, taken together with the atoms to which they are attached, may form a ring, the compounds being useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.Also disclosed are intermediates and processes useful in the preparation of the above compounds.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 7, 1997
    Assignee: Abbott Laboratories
    Inventors: Michael P. DeNinno, Richard J. Perner
  • Dopamine agonists
    Patent number: 4963568
    Abstract: Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.
    Type: Grant
    Filed: May 31, 1989
    Date of Patent: October 16, 1990
    Assignee: Abbott Laboratories
    Inventors: Robert W. Schoenleber, John W. Kebabian, Yvonne C. Martin, Michael P. DeNinno, Richard J. Perner, David M. Stout, Chi-Nung W. Hsiao, Stanley DiDomenico, Jr., John F. DeBernardis, Fatima Z. Basha, Michael D. Meyer, Biswanath De